| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells
|
Seesen, Mathurin
|
|
|
41 |
9 |
p. 1638-1648
|
artikel
|
| 2 |
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
|
Gressens, Simon B.
|
|
|
41 |
9 |
p. 1550-1553
|
artikel
|
| 3 |
Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department
|
Ford, James S.
|
|
|
41 |
9 |
p. 1611-1615
|
artikel
|
| 4 |
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study
|
Hamada, Hiroshi
|
|
|
41 |
9 |
p. 1632-1637
|
artikel
|
| 5 |
Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011–August 2019
|
Seshadri, Srihari
|
|
|
41 |
9 |
p. 1537-1540
|
artikel
|
| 6 |
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries
|
Getaneh, Abraham M.
|
|
|
41 |
9 |
p. 1623-1631
|
artikel
|
| 7 |
COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel
|
Grossman-Giron, Ariella
|
|
|
41 |
9 |
p. 1567-1572
|
artikel
|
| 8 |
Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform
|
Zhang, Yanmin
|
|
|
41 |
9 |
p. 1573-1583
|
artikel
|
| 9 |
Editorial Board/Aims and Scope
|
|
|
|
41 |
9 |
p. IFC
|
artikel
|
| 10 |
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19
|
Harbin, Ami
|
|
|
41 |
9 |
p. 1584-1588
|
artikel
|
| 11 |
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine
|
Uwamino, Yoshifumi
|
|
|
41 |
9 |
p. 1545-1549
|
artikel
|
| 12 |
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina
|
Matta, María Gabriela
|
|
|
41 |
9 |
p. 1541-1544
|
artikel
|
| 13 |
Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients
|
Stone, Addison E.
|
|
|
41 |
9 |
p. 1589-1601
|
artikel
|
| 14 |
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
|
Tsuchiya, Yumi
|
|
|
41 |
9 |
p. 1602-1610
|
artikel
|
| 15 |
Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS)
|
Patricia Wodi, A.
|
|
|
41 |
9 |
p. 1616-1622
|
artikel
|
| 16 |
Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep
|
Zabalza-Baranguá, A.
|
|
|
41 |
9 |
p. 1554-1566
|
artikel
|
Tijdschrift beschrijving